Promius Pharma, LLC

22 articles about Promius Pharma, LLC

• Upsher-Smith Laboratories Completes Acquisition Of Two Treatments For Acute Migraine In Adults

  7/20/2019

  Strategic Acquisition of Tosymra™ (sumatriptan) Nasal Spray and Zembrace® SymTouch® (sumatriptan) Injection Further Expands and Diversifies Company's Portfolio

• Dr. Reddy’s Laboratories Announces Entering into a Definitive Agreement to Sell Its Neurology Branded Products to Upsher-Smith Laboratories, LLC

  6/14/2019

  Dr. Reddy’s Laboratories Ltd. announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC, pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® 3 mg and TOSYMRA™ 10 mg, which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.

• Neurelis Announces First Product Approved Using The Company's Intravail® Platform

  1/30/2019

  Dr. Reddy's Laboratories and its U.S. subsidiary, Promius Pharma, announced U.S. FDA approval on January 28 for its migraine treatment TOSYMRA™ in the United States

• Dr. Reddy's Laboratories and Its U.S. Subsidiary, Promius Pharma, Announce FDA Approval for TOSYMRA™ (Sumatriptan Nasal Spray) 10 mg, in the U.S. Market

  1/28/2019

  Dr. Reddy's Laboratories Ltd. and its subsidiary, Promius Pharma, LLC announced the approval of TOSYMRA (previously known as DFN-02) by the U.S. Food and Drug Administration (FDA).

• Promius Pharma Announces Launch of "My Skin Matters," An Empowerment Movement for People with Skin Conditions

  10/29/2018

  Promius Pharma announced the launch of My Skin Matters, a fearless movement for people living with eczema, psoriasis, acne, and other skin conditions.

• Perrigo Confirms Patent Challenge For Generic Version Of Sernivo® Spray, 0.05%

  5/24/2018

  Perrigo Company plc (NYSE; TASE: PRGO) announced today that Promius Pharma, LLC initiated patent litigation on May 22, 2018.

• Dr. Reddy's Laboratories and its U.S. subsidiary Promius Pharma announce the filing of an NDA for its migraine candidate

  4/2/2018

  Dr. Reddy's Laboratories Ltd. and its subsidiary, Promius Pharma, LLC, today announced the filing of New Drug Application (NDA) for its migraine candidate DFN-02 with the U.S. Food and Drug Administration (USFDA).

• Promius Pharma Announces ZEMBRACE SymTouch (Sumatriptan Injection) 3 mg Achieves Primary Endpoint in Post-Approval Clinical Trial

  11/15/2017

  Overall, the trial found that a significantly higher proportion of subjects experienced migraine pain freedom at 2 hours postdose with ZEMBRACE SymTouch compared with placebo: 51.0% versus 30.8%,.

• Promius Pharma Initiates Phase III Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris

  11/9/2017

  This short-contact formulation is expected to bring a new dimension to the treatment of acne patients.

• Promius Pharma, LLC Presents Positive Results For Phase II Study Of DFN-02, A Novel Intranasal Formulation Of Sumatriptan, At 18th Congress Of The International Headache Society

  9/8/2017

• Promius Pharma, LLC Announces Positive Results For Phase II Study Of DFN-02, A Novel Intranasal Formulation Of Sumatriptan

  6/8/2017

• Promius Pharma, LLC Launches NoTime4Migraines, An Online Resource About Migraine Symptoms And Potential Treatment Options

  8/24/2016

• Promius Pharma, LLC Launches Sernivo (Betamethasone Dipropionate) Spray, 0.05%

  6/1/2016

• Promius Pharma, LLC Will Present Results Of Additional Analysis Of The American Migraine Prevalence And Prevention Study (AMPP) In Vancouver At The 68th American Academy of Neurology Annual Meeting, April 15-21, 2016

  4/19/2016

• Promius Pharma, LLC Release: ZEMBRACE Symtouch (Sumatriptan Injection) 3 Mg, Approved By The FDA In January 2016 For The Acute Treatment Of Migraine With Or Without Aura In Adults, Is Now Commercially Available In The U.S.

  4/19/2016

• Promius Pharma, LLC Receives FDA Approval For Sernivo (Betamethasone Dipropionate) Spray, 0.05%

  2/8/2016

• Dr. Reddy's Laboratories Ltd. And Its Subsidiary Promius Pharma, LLC Announce The Filing Of Three NDAs With The USFDA

  4/8/2015

• Promius Pharma, LLC and Valeant Pharmaceuticals International Form Collaboration to Market Cloderm(R) Cream in the United States

  4/1/2011

• Promius Pharma, LLC Launches Promiseb(TM) Cream

  7/28/2009

• Promius Pharma, LLC Launches Scytera(TM) (Coal Tar) Foam 2% for Treatment of Psoriasis

  1/26/2009